King Pharmaceuticals KG Legacy Reinsurance — Net loss and loss adjustment expenses

Similar metrics at other companies

EGLegacy — Incurred losses and LAE

$316M-22.4%

SPNTReinsurance — Loss and loss adjustment expenses incurred, net

$134M-31.4%

EGLegacy — Underwriting Income (Loss)

-$22M-57.1%

ACGLReinsurance — Losses and loss adjustment expenses

$948M-30.1%

ACGLReinsurance — Net Losses and Loss Adjustment Expenses Incurred

$1.15B+6.5%

EGReinsurance — Incurred Loss and Loss Adjustment Expenses

$1.88B+5.8%

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — net loss and loss adjustment expenses?

King Pharmaceuticals (KG) reported legacy reinsurance — net loss and loss adjustment expenses of $2.26M in Q1 2026.

What does legacy reinsurance — net loss and loss adjustment expenses mean?

Captures the costs associated with claims incurred and the expenses required to settle those claims within the legacy reinsurance segment. This is a critical indicator of underwriting performance and the accuracy of initial risk pricing.